Urea Breath Test Market Analysis & Forecast: 2026-2033

Urea Breath Test Market Size and Forecast – 2026 to 2033

The Urea Breath Test Market is estimated to be valued at USD 14.6 Bn in 2026 and is expected to reach USD 25.8 Bn by 2033, exhibiting a compound annual growth rate (CAGR) of 7.3% from 2026 to 2033.

Key Takeaways

• By Test Type, Laboratory Based Test hold the largest market share of 52.2% in 2026 owing to the rising prevalence of h. pylori and gi diseases.
• By Product, Breath Analyzer expected to hold largest market share of 51.6% in 2026 owing to its preference for non‑invasive and patient‑friendly diagnostics.
• By Instrument, Mass Spectrometer acquired the prominent market share of 43.3% in 2026 owing to the superior accuracy, sensitivity & precision.
• By End User, Hospitals capture the largest market share of 37.7% in 2026 owing to the high patient volume & clinical demand.
• By Region, North America dominates the overall market with an estimated share of 41.1% in 2026 owing to the advanced healthcare infrastructure.

Market Overview

The global Urea Breath Test (UBT) market is growing as more people contract Helicobacter pylori and awareness of gastrointestinal diseases increases. Hospitals, diagnostic laboratories, and clinics actively use UBT for accurate diagnosis and post-treatment monitoring because it offers a non-invasive, patient-friendly option. Companies are improving test accuracy and efficiency through technological advancements such as portable analyzers and mass spectrometry systems. Strong healthcare infrastructure, supportive reimbursement policies, and seamless integration into clinical workflows continue to drive widespread adoption of UBT worldwide.

Current Events and their Impact on the Urea Breath Test Market

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights

To learn more about this report, Download Free Sample

Urea Breath Test Market Insights, By Product - Breath Analyzer contribute the highest share of the market owing to its technological advancements in analyzer devices

Breath Analyzer expected to hold largest market share of 51.6% in 2026. The Urea Breath Test (UBT) market is increasingly adopting breath analyzers as healthcare providers seek rapid, non-invasive, and patient-friendly methods to detect Helicobacter pylori. Clinicians actively use these devices for their portability, ease of operation, and ability to deliver reliable results quickly at point-of-care settings. Ongoing technological advancements, such as automated analysis and improved sensor accuracy, boost clinical confidence. Growing awareness of gastrointestinal health and the integration of these devices into hospitals and outpatient clinics further drive their widespread use for effective diagnosis and monitoring. For instance, Meridian Bioscience, Inc., a global provider of diagnostic solutions and life science materials, announced that the FDA has cleared Premier HpSA FLEX to diagnose H. pylori in preserved and unpreserved stools. This product complements Meridian’s H. pylori portfolio, including BreathID urea breath tests, Curian® HpSA, and ImmunoCard® Stat! HpSA.

Urea Breath Test Market Insights, By Test Type - Laboratory Based Test contribute the highest share of the market owing to its integration into clinical workflows and guidelines

Laboratory Based Test hold the largest market share of 52.2% in 2026. The demand for laboratory-based Urea Breath Tests (UBT) is rising as healthcare providers seek more precise and reliable Helicobacter pylori diagnostics. Laboratories deliver high-throughput testing with exceptional sensitivity and accuracy, enabling clinicians to confirm infections and monitor treatment outcomes effectively. Expanding laboratory infrastructure, advancing analytical technologies, and integrating UBT into standard diagnostic protocols actively drive adoption. Hospitals and research centers rely on lab-based tests for their reproducibility and detailed quantitative results, reinforcing their central role in comprehensive gastrointestinal care. For instance, in February 2026, Zandra Healthcare has opened a Metabolic Health Centre in India to tackle obesity, diabetes, and related complications. The centre uses an integrated diagnostic approach, offers Cryolipolysis for fat reduction, and performs Urea Breath Tests to detect H. pylori infections.

Urea Breath Test Market Insights, By Instrument - Mass Spectrometer contribute the highest share of the market owing to its increasing healthcare investment & infrastructure

Mass Spectrometer acquired the prominent market share of 43.3% in 2026. The Urea Breath Test (UBT) market increasingly relies on mass spectrometers as healthcare providers and laboratories seek highly accurate and sensitive detection of Helicobacter pylori. Hospitals and diagnostic labs use these instruments for precise isotope analysis and consistent quantitative results, supporting both diagnosis and treatment monitoring. Advances in automation, faster data processing, and seamless integration into laboratory workflows improve operational efficiency. Research centers and specialized clinics actively adopt mass spectrometry to meet the demand for reliable, reproducible results, cementing its role as a critical tool in gastrointestinal diagnostics. For instance, in June 2025, Thermo Fisher Scientific introduced two advanced mass spectrometers and highlighted its multi-omics strategy at the American Society for Mass Spectrometry (ASMS) conference in Baltimore, Maryland.

Urea Breath Test Market Insights, By End User - Hospitals contribute the highest share of the market owing to its high patient volume & clinical demand

Hospitals capture the largest market share of 37.7% in 2026. Hospitals actively drive growth in the Urea Breath Test (UBT) market by adopting non-invasive, patient-friendly diagnostics to detect Helicobacter pylori. They apply UBT to manage large patient volumes efficiently, streamline gastrointestinal diagnostic workflows, and monitor treatment progress. Hospitals leverage the test’s high accuracy, seamless integration into clinical protocols, and support for multidisciplinary care teams. Expanding infrastructure, availability of advanced diagnostic equipment, and a focus on early detection motivate hospitals to establish UBT as a standard tool for comprehensive gastrointestinal care.

Regional Insights

To learn more about this report, Download Free Sample

North America Urea Breath Test Market Trends

North America dominates the overall market with an estimated share of 41.10% in 2026. The North America Urea Breath Test (UBT) market is expanding as healthcare providers respond to growing awareness of gastrointestinal health and the increasing prevalence of Helicobacter pylori infections. Hospitals and outpatient clinics actively adopt non-invasive, rapid, and accurate UBT methods, integrating them into routine diagnostic workflows. Companies introduce technological innovations, such as portable analyzers and advanced mass spectrometry systems, to improve testing efficiency and reliability. Strong healthcare infrastructure, supportive reimbursement policies, and adherence to clinical guidelines drive widespread UBT adoption across medical facilities in the region. For instance, Phathom Pharmaceuticals, launched by Takeda and Frazier Healthcare Partners, developed VOQUEZNA, a first-in-class oral treatment combining vonoprazan with antibiotics to treat H. pylori infection in adults.

Asia Pacific Urea Breath Test Market Trends

The Asia Pacific Urea Breath Test (UBT) market is growing rapidly as healthcare providers respond to the high prevalence of Helicobacter pylori infections. Hospitals and diagnostic centers actively adopt non-invasive, accurate, and patient-friendly UBT methods to enhance diagnosis and monitor treatment outcomes. Increasing investments in healthcare infrastructure, modernization of laboratories, and greater awareness of gastrointestinal diseases drive adoption. Companies introduce technological improvements in portable analyzers and automated systems, boosting efficiency and enabling broader implementation across both urban and emerging healthcare markets throughout Asia Pacific.

United States Urea Breath Test Market Trends

The United States Urea Breath Test (UBT) market is growing as healthcare providers focus on early and accurate detection of Helicobacter pylori infections. Hospitals, clinics, and diagnostic laboratories actively use non-invasive, patient-friendly UBT methods to improve diagnosis and track treatment outcomes. Companies continually introduce technological innovations, such as portable analyzers and advanced mass spectrometry systems, to boost test speed and reliability. Strong healthcare infrastructure, supportive insurance coverage, and adherence to clinical guidelines drive widespread adoption, making UBT a central diagnostic tool in U.S. gastrointestinal care.

China Urea Breath Test Market Trends

The China Urea Breath Test (UBT) market is growing as hospitals and diagnostic centers actively address the high prevalence of Helicobacter pylori infections. Healthcare providers increasingly use non-invasive, accurate, and patient-friendly UBT methods to improve diagnosis and track treatment outcomes. Expanding investments in healthcare infrastructure, laboratory modernization, and rising public awareness of gastrointestinal health drive adoption. Companies introduce technological advancements, including portable analyzers and automated systems, to boost testing efficiency and enable wider deployment across both urban hospitals and regional healthcare facilities throughout China.

End-user Feedback and Unmet Needs in the Urea Breath Test Market

• Demand for Faster Results: End-users, including clinicians and laboratories, often seek quicker turnaround times for UBT results to make timely treatment decisions. While traditional lab-based methods provide high accuracy, some users report delays, highlighting the need for rapid yet reliable testing solutions that balance speed with diagnostic precision.
• Need for Portability and Point-of-Care Use: Clinicians in outpatient clinics and remote areas emphasize the demand for portable, easy-to-use UBT analyzers. Existing equipment can be bulky or require specialized lab setups. Users express the need for compact, user-friendly devices that can deliver accurate results outside centralized laboratories.
• Desire for Enhanced Accuracy and Sensitivity: While UBT is considered highly reliable, end-users report occasional false negatives, particularly in patients on antibiotics or proton pump inhibitors. There is an unmet need for technologies that maintain high sensitivity and specificity across diverse patient conditions, ensuring consistent and clinically actionable results.

Urea Breath Test Market Trend

Rising Preference for Non-Invasive Diagnostics

Healthcare providers increasingly favor non-invasive testing methods like UBT over traditional invasive procedures such as endoscopy. Patients benefit from a painless, quick, and convenient diagnostic experience. This trend reflects a broader shift toward patient-centered care, where minimizing discomfort, improving compliance, and reducing procedure-related risks are prioritized. Clinicians also value the efficiency of UBT for screening, diagnosis, and post-treatment monitoring, particularly in outpatient and high-volume hospital settings.

Technological Advancements in Analyzer Systems

The UBT market is evolving with innovations in breath analyzers and mass spectrometry systems. Portable analyzers, automated sample processing, and enhanced sensor accuracy improve diagnostic speed and reliability. Integration of digital tools and software for data management allows laboratories and clinics to streamline workflows, reduce human error, and provide actionable results faster. Continuous technological development strengthens clinician confidence in UBT and supports wider adoption across hospitals, outpatient centers, and research institutions.

Market Report Scope

Urea Breath Test Market Report Coverage

Urea Breath Test Market News

In January 2026, AIG Hospitals launched PYtest, India’s first clinically validated breath test for detecting Helicobacter pylori infection, developed by Nobel Laureate Barry Marshall.

Analyst Opinion (Expert Opinion)

• The Urea Breath Test (UBT) market is experiencing a phase where clinical utility and epidemiological necessity intersect in meaningful ways. The ubiquity of Helicobacter pylori infection—affecting over half of the global population and reaching prevalence rates of up to 60‑plus percent in certain high‑risk populations—demands diagnostic tools that deliver both precision and patient acceptance, a criterion that UBT consistently meets with pooled diagnostic sensitivity and specificity surpassing 90 % in rigorous meta‑analyses. This underscores a critical shift from reliance on invasive procedures toward evidence‑based non‑invasive methods that clinicians trust to inform treatment decisions and confirm eradication.
• In North America alone, advanced healthcare systems have integrated point‑of‑care UBT extensively, particularly in outpatient and gastroenterology clinics, reflecting clinician confidence in the test’s real‑world performance characteristics. However, the market’s evolution is not without friction. Diagnostic standardization remains inconsistent across regions, as regulatory frameworks differ and variations in test protocols can lead to performance disparities, complicating multinational clinical deployment and comparative outcome analyses. Consequently, stakeholders with the greatest influence on UBT’s growth will be those who not only champion its accuracy but also actively contribute to harmonizing quality standards, training, and integration into clinical algorithms that prioritize early detection and antibiotic stewardship in gastrointestinal care.

Market Segmentation

• By Test Type
  • Point-of-Care Tests (POCT)
  • Laboratory Based Test
• By Product
  • Breath Analyzer
  • UBT-Kits
• By Instrument
  • Mass Spectrometer
  • Infrared Spectrometer
  • Laser Assisted Rationalizer
• By End User
  • Hospitals
  • Clinics
  • Diagnostic Centers (Standalone Labs and Private Lab Networks)
• By Regional Insights
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Kibion AB (Mayoly Spindler)
  • Avanos Medical, Inc.
  • Quest Diagnostics
  • Beijing Richen-Force Science & Technology Co., Ltd.
  • Paladin Labs Inc.
  • Beijing Binal Health Bio- Sci & Tech Co., Ltd.
  • AB ANALITICA s.r.l.
  • Otsuka Holdings Co., Ltd.
  • Sercon Group
  • Campro Scientific GmbH
  • Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd.
  • Avisa Diagnostics
  • INFAI GmbH
  • Meridian Bioscience, Inc.
  • Metabolic Solutions, Inc.
  • Laboratory Corporation of America Holdings
  • Gulf Coast Scientific, Inc.
  • FAN GmbH
  • Kizlon Medical

Sources

Primary Research interviews

• Gastroenterologists and hepatologists
• Clinical laboratory directors
• Hospital procurement managers
• Diagnostic equipment distributors
• Medical device regulatory experts

Databases

• PubMed
• ClinicalTrials.gov
• WHO Global Health Observatory
• FDA medical device database
• CDC (Centers for Disease Control and Prevention) data portals

Magazines

• Diagnostic Imaging
• Clinical Laboratory News
• Medical Device & Diagnostic Industry (MD+DI)
• Laboratory Equipment

Journals

• Journal of Clinical Gastroenterology
• Alimentary Pharmacology & Therapeutics
• Helicobacter
• American Journal of Gastroenterology
• Clinical Chemistry

Newspapers

• The New York Times – Health Section
• The Guardian – Science & Health
• The Washington Post – Health & Science

Associations

• American Gastroenterological Association (AGA)
• European Helicobacter and Microbiota Study Group (EHMSG)
• World Gastroenterology Organisation (WGO)
• American Clinical Laboratory Association (ACLA)

Public Domain sources

• WHO reports on Helicobacter pylori prevalence
• National Health Service (NHS) guidelines on UBT
• CDC infection control and diagnostic statistics
• Open-access epidemiological studies on gastric diseases

Proprietary Elements

• CMI Data Analytics Tool, and Proprietary CMI Existing Repository of information for last 8 years